SMARCA1 and epithelioid sarcoma: There is current FDA approval for TAZ in epithelioid sarcoma, which exhibits PRC2 hyperactivation resulting from SWI/SNF complex mutations, and follicular lymphoma, characterized by EZH2 gain-of-function mutations (8,9).